Glenmede Trust’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,099
| Closed | -$27K | – | 1855 |
|
|
2020
Q3 | $27K | Sell |
2,099
-24
| -1% | -$304 | ﹤0.01% | 1501 |
|
|
2020
Q2 | $24K | Sell |
2,123
-2,154
| -50% | -$30.6K | ﹤0.01% | 1522 |
|
|
2020
Q1 | $116K | Hold |
4,277
| – | – | ﹤0.01% | 1372 |
|
|
2019
Q4 | $116K | Sell |
4,277
-1,882
| -31% | -$51.8K | ﹤0.01% | 1372 |
|
|
2019
Q3 | $175 | Buy |
6,159
+109
| +2% | +$3.18K | ﹤0.01% | 1221 |
|
|
2019
Q2 | $167 | Hold |
6,050
| – | – | ﹤0.01% | 1221 |
|
|
2019
Q1 | $200 | Sell |
6,050
-829
| -12% | -$25.2K | ﹤0.01% | 1174 |
|
|
2018
Q4 | $199 | Buy |
+6,879
| New | +$247K | ﹤0.01% | 1119 |
|
|
2018
Q3 | – | Sell |
-2,345
| Closed | -$87K | – | 1682 |
|
|
2018
Q2 | $87K | Sell |
2,345
-51
| -2% | -$1.72K | ﹤0.01% | 1294 |
|
|
2018
Q1 | $81K | Hold |
2,396
| – | – | ﹤0.01% | 1464 |
|
|
2017
Q4 | $81K | Buy |
2,396
+243
| +11% | +$8.2K | ﹤0.01% | 1464 |
|
|
2017
Q3 | $77K | Hold |
2,153
| – | – | ﹤0.01% | 1490 |
|
|
2017
Q2 | $40K | Hold |
2,153
| – | – | ﹤0.01% | 1684 |
|
|
2017
Q1 | $40K | Buy |
2,153
+1,000
| +87% | +$17.7K | ﹤0.01% | 1684 |
|
|
2016
Q4 | $18K | Sell |
1,153
-150
| -12% | -$2.71K | ﹤0.01% | 1930 |
|
|
2016
Q3 | $26K | Sell |
1,303
-12,101
| -90% | -$307K | ﹤0.01% | 1852 |
|
|
2016
Q2 | $409K | Buy |
13,404
+12,054
| +893% | +$419K | ﹤0.01% | 986 |
|
|
2016
Q1 | $50K | Buy |
1,350
+35
| +3% | +$1.32K | ﹤0.01% | 1518 |
|
|
2015
Q4 | $56K | Buy |
1,315
+32
| +2% | +$1.35K | ﹤0.01% | 1530 |
|
|
2015
Q3 | $48K | Buy |
1,283
+4
| +0.3% | +$142 | ﹤0.01% | 1598 |
|
|
2015
Q2 | $43K | Sell |
1,279
-462,537
| -100% | -$15.7M | ﹤0.01% | 1683 |
|
|
2015
Q1 | $16.4M | Buy |
463,816
+4,266
| +0.9% | +$153K | 0.12% | 277 |
|
|
2014
Q4 | $15.7M | Buy |
459,550
+26,366
| +6% | +$936K | 0.12% | 261 |
|
|
2014
Q3 | $16.7M | Buy |
433,184
+22,661
| +6% | +$846K | 0.15% | 217 |
|
|
2014
Q2 | $16M | Buy |
410,523
+36,362
| +10% | +$1.35M | 0.14% | 220 |
|
|
2014
Q1 | $12.8M | Buy |
374,161
+54,478
| +17% | +$1.69M | 0.12% | 249 |
|
|
2013
Q4 | $6.71M | Sell |
319,683
-65,708
| -17% | -$1.66M | 0.07% | 334 |
|
|
2013
Q3 | $8.92M | Buy |
385,391
+115,983
| +43% | +$3.3M | 0.11% | 251 |
|
|
2013
Q2 | $7.24M | Buy |
+269,408
| New | +$7.81M | 0.09% | 247 |
|
Other funds holding MYGN
CCM
GCM
Glenmede Trust's MYGN Position: Q4 2020 in Review
Glenmede Trust sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 2,099 shares — an estimated $27K sold.
Glenmede Trust first reported a position in MYGN in Q2 2013 and held it in 29 quarters. The position peaked at $16.7M in Q3 2014. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.
- Glenmede Trust reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
- Glenmede Trust sold 2,099 Myriad Genetics shares in Q4 2020, an estimated $27K.
- Glenmede Trust first reported a position in Myriad Genetics in Q2 2013 and held it in 29 quarters.
- Glenmede Trust's Myriad Genetics position peaked at $16.7M in Q3 2014.
- 187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.
Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.